In the last decade, next generation sequencing studies have deciphered the MCL mutational landscape identifying recurrent mutations (TP53, ATM, NOTCH1/2, CCND1, HNRNPH1, KMT2D, ARID1A, SMARCA4) [5, 6] that contribute to MCL pathogenesis and resistance to chemoimmunotherapy or targeted therapies [7]. The gene discussed is CCND1; the disease is mantle cell lymphoma.